Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study to Evaluate the Efficacy of DB107-RRV (Formerly Toca511), Administered to Subjects At Time of Resection and Intravenously Thereafter, in Combination with DB107-FC (Formerly Toca FC) and Radiation Therapy or DB107-FC, Temozolomide (TMZ) and Radiation Therapy in Patients with Newly Diagnosed High Grade Glioma

Next Previous
Trial Profile

A Phase I/IIa Study to Evaluate the Efficacy of DB107-RRV (Formerly Toca511), Administered to Subjects At Time of Resection and Intravenously Thereafter, in Combination with DB107-FC (Formerly Toca FC) and Radiation Therapy or DB107-FC, Temozolomide (TMZ) and Radiation Therapy in Patients with Newly Diagnosed High Grade Glioma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 05 Mar 2025 According to Anova media release company announced enrollment of the first two patients in the highly anticipated study of DB107 for the treatment of brain tumors.
  • 14 Feb 2025 Planned End Date changed from 31 Jan 2040 to 31 Jan 2042.
  • 14 Feb 2025 Planned primary completion date changed from 31 Jan 2040 to 31 Jan 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top